64Cu-DOTA-rituximab (Stanford University)

N/A

Report date: 2025/10/20 14:27:11

Base Information

Drug Name64Cu-DOTA-rituximab (Stanford University)

Drug Alias Name[64Cu]Rituximab64Cu-DOTA-RituximabCu-64 RituximabCu64-DOTA-rituximab[64Cu]DOTA-rituximab

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Nuclides > Copper > 64Cu +[5]

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesStanford University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesStanford University

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A